Gene-based drug developer GenVec Inc. said Tuesday a mid-stage clinical trail showed TNFerade, a pancreatic cancer treatment, helped improve the survival rate among patients in the study.
"The magnitude of the survival benefit demonstrated by TNFerade to date may allow GenVec to implement modifications to the study that, assuming this trend continues, could potentially accelerate its conclusion and allow an earlier review by FDA than previously anticipated," said Mark Thornton, senior vice president of product development, in a prepared statement.
Data for the first 51 patients enrolled in the study, some followed for as long as 18 months, showed a 42.5 percent absolute increase in overall survival with the addition of TNFerade to standard of care, GenVac said. The company hopes to eventually enroll 330 patients in the study.
Subscribe via RSS
